http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2099772-A1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 |
| filingDate | 1992-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fd34aa5e9b96a319338113d6b66fb31 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd2c7aec9daab338424d86b036ede0d5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_279ec0a73b4cd9054c8b465e30c9cf99 |
| publicationDate | 1992-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2099772-A1 |
| titleOfInvention | Anti-hiv activity of liposomal nystatin and amphotericin b |
| abstract | ANTI-HIV ACTIVITY OF LIPOSOMAL NYSTATIN AND AMPHOTERICIN B ABSTRACT OF THE INVENTION A method is disclosed for inhibiting the replication of HIV-1 virus. The method includes the step of administering to a subject which is infected with HIV-1 a pharmaceutically effective amount of a liposomal composition which comprises at least one lipid and a polyene selected from nystatin and amphotericin B. Such liposomal compositions have been found to be selectively toxic for HIV-infected cells.The composition preferably comprises nystatin, dimyristoyl phosphatidyl choline, and dimyristoyl phosphatidyl glycerol, with the weight ratio of the latter two components being about 7:3. |
| priorityDate | 1991-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 105.